MY160357A - Thienopyridone derivatives as amp-activated protein kinase (ampk) activators - Google Patents

Thienopyridone derivatives as amp-activated protein kinase (ampk) activators

Info

Publication number
MY160357A
MY160357A MYPI2010005160A MYPI2010005160A MY160357A MY 160357 A MY160357 A MY 160357A MY PI2010005160 A MYPI2010005160 A MY PI2010005160A MY PI2010005160 A MYPI2010005160 A MY PI2010005160A MY 160357 A MY160357 A MY 160357A
Authority
MY
Malaysia
Prior art keywords
ampk
activators
protein kinase
activated protein
thienopyridone derivatives
Prior art date
Application number
MYPI2010005160A
Other languages
English (en)
Inventor
Daniel Cravo
Franck Lepifre
Sophie Hallakou-Bozec
Chiristine Charon
Original Assignee
Merck Patent Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40756916&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MY160357(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Merck Patent Gmbh filed Critical Merck Patent Gmbh
Publication of MY160357A publication Critical patent/MY160357A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D333/38—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Emergency Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Endocrinology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Epidemiology (AREA)
  • Plural Heterocyclic Compounds (AREA)
MYPI2010005160A 2008-05-05 2009-04-08 Thienopyridone derivatives as amp-activated protein kinase (ampk) activators MY160357A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP08290423 2008-05-05

Publications (1)

Publication Number Publication Date
MY160357A true MY160357A (en) 2017-02-28

Family

ID=40756916

Family Applications (1)

Application Number Title Priority Date Filing Date
MYPI2010005160A MY160357A (en) 2008-05-05 2009-04-08 Thienopyridone derivatives as amp-activated protein kinase (ampk) activators

Country Status (26)

Country Link
US (1) US8604202B2 (https=)
EP (1) EP2280952B1 (https=)
JP (1) JP5536757B2 (https=)
KR (2) KR20160038065A (https=)
CN (1) CN102015676B (https=)
AR (1) AR071530A1 (https=)
AU (1) AU2009243811B2 (https=)
BR (1) BRPI0910832B8 (https=)
CA (1) CA2723429C (https=)
CO (1) CO6331304A2 (https=)
CY (1) CY1113112T1 (https=)
DK (1) DK2280952T3 (https=)
EA (1) EA020773B1 (https=)
EC (1) ECSP10010654A (https=)
ES (1) ES2388485T3 (https=)
HR (1) HRP20120549T1 (https=)
IL (1) IL208988A (https=)
MX (1) MX2010011916A (https=)
MY (1) MY160357A (https=)
NZ (1) NZ589690A (https=)
PL (1) PL2280952T3 (https=)
PT (1) PT2280952E (https=)
SI (1) SI2280952T1 (https=)
UA (1) UA103617C2 (https=)
WO (1) WO2009135580A1 (https=)
ZA (1) ZA201008722B (https=)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011107494A1 (de) 2010-03-03 2011-09-09 Sanofi Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
US20130085169A1 (en) 2010-04-02 2013-04-04 Inserm (Institut National De La Sante Et De La Recherche Medicale) Methods and compositions comprising ampk activator (metformin/troglitazone) for the treatment of myotonic dystrophy type 1 (dm1)
US8530413B2 (en) 2010-06-21 2013-09-10 Sanofi Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
TW201215387A (en) 2010-07-05 2012-04-16 Sanofi Aventis Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
TW201221505A (en) 2010-07-05 2012-06-01 Sanofi Sa Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
TW201215388A (en) 2010-07-05 2012-04-16 Sanofi Sa (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
JP5990170B2 (ja) * 2010-09-01 2016-09-07 バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツングＢａｙｅｒ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ ＧｍｂＨ 除草活性を有するケトスルタム類及びジケトピリジン類
CA2830706A1 (en) * 2011-03-07 2012-09-13 Glaxosmithkline Llc Quinolinone derivatives
WO2013037390A1 (en) 2011-09-12 2013-03-21 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
EP2760862B1 (en) 2011-09-27 2015-10-21 Sanofi 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
US8889730B2 (en) 2012-04-10 2014-11-18 Pfizer Inc. Indole and indazole compounds that activate AMPK
EP2679591A1 (en) 2012-06-29 2014-01-01 Poxel Thienopyridone derivatives useful as activators of AMPK
JP6064062B2 (ja) 2013-03-15 2017-01-18 ファイザー・インク Ａｍｐｋを活性化させるインダゾール化合物
US10143703B2 (en) 2014-01-02 2018-12-04 Massachusetts Eye And Ear Infirmary Treating ocular neovascularization
WO2015114663A1 (en) 2014-01-30 2015-08-06 Council Of Scientific & Industrial Research Novel thieno [2,3-d]pyrimidin-4(3h)-one compounds with antimycobacterial properties
WO2016205534A1 (en) * 2015-06-16 2016-12-22 Lazo John S Inhibitors of ptp4a3 for the treatment of cancer
RS61919B1 (sr) 2015-06-25 2021-06-30 Univ Health Network Inhibitori hpk1 i postupci za njihovo korišćenje
WO2017055925A2 (en) 2015-09-30 2017-04-06 Instituto De Medicina Molecular Methods for attenuating parasite virulence
US11584755B2 (en) 2017-09-26 2023-02-21 Ideaya Biosciences, Inc. Dihydrothieno[3,2-b]pyridine compounds
WO2019106087A1 (en) * 2017-11-29 2019-06-06 Syddansk Universitet Ampk inhibitors
WO2021236617A1 (en) 2020-05-19 2021-11-25 Kallyope, Inc. Ampk activators
CA3183575A1 (en) 2020-06-26 2021-12-30 Iyassu Sebhat Ampk activators
EP4221700A1 (en) 2020-09-30 2023-08-09 Bioverativ Therapeutics Inc. Ampk activators and methods of use thereof
WO2022106892A1 (en) 2020-11-17 2022-05-27 Instituto De Medicina Molecular Anti-malarial compounds
JP2024540522A (ja) 2021-11-19 2024-10-31 ザ・ブロード・インスティテュート・インコーポレイテッド キナーゼを標的結合部分で標識するための二官能性キメラ分子及びその使用方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8627698D0 (en) * 1986-11-20 1986-12-17 Boots Co Plc Therapeutic agents
DE4444815A1 (de) 1994-12-15 1996-06-20 Merck Patent Gmbh Thienopyridone
AR040123A1 (es) 2002-05-31 2005-03-16 Upjohn Co Compuestos tiofeno, antihelminticos e insecticidas
US7119205B2 (en) * 2003-05-16 2006-10-10 Abbott Laboratories Thienopyridones as AMPK activators for the treatment of diabetes and obesity
WO2006093518A2 (en) * 2004-06-25 2006-09-08 Apath, Llc Thienyl compounds for treating virus-related conditions
US7563813B2 (en) * 2005-05-13 2009-07-21 Wyeth Iminothiazolidinone derivatives as SFRP-1 antagonists
EP1754483A1 (en) 2005-08-18 2007-02-21 Merck Sante Use of thienopyridone derivatives as AMPK activators and pharmaceutical compositions containing them
WO2007072094A1 (en) * 2005-12-20 2007-06-28 Richter Gedeon Nyrt. New compounds
MY155836A (en) * 2008-04-11 2015-12-15 Merck Patent Gmbh Thienopyridone derivatives as amp-activated protein kinase (ampk) activators

Also Published As

Publication number Publication date
IL208988A0 (en) 2011-01-31
EA020773B1 (ru) 2015-01-30
BRPI0910832B1 (pt) 2020-09-15
DK2280952T3 (da) 2012-07-23
KR20160038065A (ko) 2016-04-06
PT2280952E (pt) 2012-09-28
EA201001733A1 (ru) 2011-06-30
JP2011519876A (ja) 2011-07-14
KR101648593B1 (ko) 2016-08-16
ECSP10010654A (es) 2011-01-31
WO2009135580A1 (en) 2009-11-12
BRPI0910832A8 (pt) 2016-07-12
MX2010011916A (es) 2010-11-26
HRP20120549T1 (hr) 2012-07-31
AU2009243811B2 (en) 2014-04-10
EP2280952B1 (en) 2012-06-27
ZA201008722B (en) 2012-01-25
PL2280952T3 (pl) 2012-10-31
CA2723429C (en) 2016-10-11
US8604202B2 (en) 2013-12-10
CN102015676A (zh) 2011-04-13
BRPI0910832A2 (pt) 2015-08-11
EP2280952A1 (en) 2011-02-09
CO6331304A2 (es) 2011-10-20
CY1113112T1 (el) 2016-04-13
HK1156313A1 (en) 2012-06-08
JP5536757B2 (ja) 2014-07-02
AR071530A1 (es) 2010-06-23
ES2388485T3 (es) 2012-10-15
CN102015676B (zh) 2014-05-28
US20110060001A1 (en) 2011-03-10
IL208988A (en) 2016-02-29
AU2009243811A1 (en) 2009-11-12
UA103617C2 (ru) 2013-11-11
SI2280952T1 (sl) 2012-09-28
CA2723429A1 (en) 2009-11-12
KR20110010757A (ko) 2011-02-07
NZ589690A (en) 2012-07-27
BRPI0910832B8 (pt) 2021-05-25

Similar Documents

Publication Publication Date Title
MY160357A (en) Thienopyridone derivatives as amp-activated protein kinase (ampk) activators
MY155836A (en) Thienopyridone derivatives as amp-activated protein kinase (ampk) activators
EA201001647A1 (ru) Производные бензофурана, бензотиофена, бензотиазола в качестве fxr модуляторов
EA201190158A1 (ru) Производные бензофуранила для применения в качестве ингибиторов глюкокиназы
MX2010009752A (es) Compuestos de oxadiazoantraceno para el tratamiento de diabetes.
EA200970967A1 (ru) Оксадиазол замещенные производные индазола для применения в качестве агонистов сфингозин 1-фосфата (sip)
MX2009004716A (es) Compuestos y composiciones en la forma de inhibidores de quinasa de proteina.
ATE517882T1 (de) Chinolinderivate
WO2005075425A3 (en) Substituted bisarylurea derivatives as kinase inhibitors
WO2008094992A3 (en) 2-aminopyridine derivatives useful as kinase inhibitors
UA95644C2 (ru) Пиридазиноновые производные, фармацевтическая композиция и способ лечения заболеваний
PH12012501122A1 (en) Pteridinones as inhibitors of polo-like kinase
NO20082124L (no) Bifenyloksyeddiksyrederivater for behandling av respiratorisk sykdom
MX2011006006A (es) Compuestos, composicion farmaceutica y metodos para utilizarse en el tratamiento de trastornos metabolicos.
WO2008049855A3 (en) 7-azaindole derivatives as c-met kinase inhibitors
WO2009094560A3 (en) Thienopyranones as kinase inhibitors
MX2007004248A (es) Derivados heterociclicos de bisarilurea sustituidos como inhibidores de cinasa.
MX2012001529A (es) Derivados de 3-heteroaril-metil-imidazo-[1,2-b]-piridazin-6-ilo como moduladores de cinasa de tirosina c-met.
WO2008028935A3 (en) Pyridinyl-pyrimidine derivatives useful as potassium channel modulating agents
TW200637817A (en) 5-aminoindole derivatives
WO2008098143A3 (en) Antimicrobial compounds and methods of use
SI1745010T1 (sl) Substituirani cikloheksil-1,4-diaminski derivati
BR112012012000A2 (pt) derivados de quinazolina
ATE496899T1 (de) Tetrahydro- und dihydrochinazolinone
MX2010008923A (es) Compuesto (r)-n*6*-etil-6,7-dihidro-5h-indeno(5,6-d)tiazol-2,6-dia mina y su uso como antipsicotico.